All In Biotech

NDA 219840 · Bracco

E-Z-Disk

Barium Sulfate · Oral · Radiographic Contrast Agent

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 1, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

4 Phase 3, 5 recruiting

FAERS reports

259

194 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 29, 2025.

E-Z-DISK is indicated for the evaluation of esophageal patency in adults and pediatric patients aged 12 years and older. E-Z-DISK is a radiographic contrast agent indicated for the evaluation of esophageal patency in adults and pediatric patients aged 12 years and older. ( 1 )

Mechanism: E-Z-DISK is formulated to pass through the esophagus into the stomach when the esophageal lumen is greater than 11.5 mm to 13.5 mm (0.45 inch to 0.53 inch) in diameter. Due to its high atomic number, barium is opaque to X-rays and therefore acts as a positive contrast agent for radiographic studies.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 1, 2025 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewLetter
1 products under this application
  • E-Z-DISK · BARIUM SULFATE 700MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Barium" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal failure18
  • acute kidney injury17
  • urticaria17
  • chronic kidney disease15
  • diarrhoea14
  • rash14
  • dyspnoea13
  • drug hypersensitivity12
  • pruritus12
  • vomiting12
  • abdominal pain10
  • aspiration10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20073
20088
20094
20108
201112
201212
201317
201413
20159
201618
201723
201818
201916
202011
202118
202220
202316
202410
202512
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 728 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.